• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers

    Diabetes Technology Manufacturers Seemingly on a Sugar Rush

    Post-Pandemic Partnerships: A Full-Service Outsourcing Discussion

    Discovering the Value of Surface Treatments and Coatings for Medtech
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    New Breast Implant Surgery Guidelines to Enhance Patient Safety

    Rhythm Management Group Debuts RhythmSynergy Tech Platform

    FDA Approves Trial Completion for Virtual Incision's MIRA Platform

    Thermo Fisher Scientific, Matrix Clinical Trials Enhance Research Solutions

    Medtronic, DaVita to Create New Kidney Care Firm
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers

    Diabetes Technology Manufacturers Seemingly on a Sugar Rush

    Post-Pandemic Partnerships: A Full-Service Outsourcing Discussion

    Discovering the Value of Surface Treatments and Coatings for Medtech
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Injecting Neurostimulators into Blood Vessels (We Swear, It’s Not Sci-Fi)

    Understanding the Costs of Care in the OR

    Sick of Being Sick: Pandemic Fatigue Flares at AAOS

    Managing Critical Healthcare Supply Chains in Turbulent Times

    To Drive Value, Human Capital Leaders Turn to Outsourced Solutions
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Concise Engineering

    Xact Wire EDM Corp.

    Arthur G. Russell Co. Inc., The

    BMP Medical

    Trademark Plastics Inc.
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    3D Printing in Dental Prosthodontics, Orthodontics, and Surgery

    What New Tech Can Improve Your Medical Manufacturing Plant?

    Why Medical Device Firms Must Navigate the Muddy Waters of ESG Requirements

    Medical Device Servicing vs. Remanufacturing

    Digital Marketplaces for Medical Equipment Come of Age
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Concise Engineering

    Xact Wire EDM Corp.

    Arthur G. Russell Co. Inc., The

    BMP Medical

    Trademark Plastics Inc.
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Breaking News

    AtriCure Announces Results from CONVERGE IDE Clinical Trial

    Study showed an 18 percent difference between the Convergent arm and the control arm in evaluable patients at 12 months.

    Related CONTENT
    • Breakthrough Device Designation Granted for New Neuromodulation Platform
    • Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech
    • Improved Outcomes Proven With Insulet’s Omnipod 5 System
    • Masimo Launches Single-Patient-Use rainbow SuperSensor in Europe
    • Vertigo Treatment Receives FDA Breakthrough Device Designation
    Business Wire07.10.20
    AtriCure Inc., an innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced results from the CONVERGE IDE clinical trial. This first-of-its-kind trial, designed to demonstrate superiority, showed an 18 percent difference in favor of the hybrid Convergent procedure as compared to endocardial catheter ablation alone. 
     
    “The CONVERGE study is a monumental step forward in the market focused on the most difficult to treat Afib patients, those with persistent or long-standing persistent forms of the disease,” said Michael Carrel, president and CEO at AtriCure. “This patient population represents many millions of patients and more than two-thirds of all diagnosed Afib patients. The study results presented at HRS mark a major milestone for the CONVERGE study and we look forward to working with the FDA moving forward.”
     
    The CONVERGE IDE trial’s primary effectiveness endpoint is freedom from Afib, atrial tachycardia (AT), and atrial flutter (AFL), absent class I and III anti-arrhythmic drugs (AADs) except for a previously failed or demonstrated intolerance to class I or III AADs, with no increase in dosage following the three-month blanking period through the 12-months post procedure follow-up visit. The primary safety endpoint is the incidence of protocol-defined major adverse events (MAEs) for subjects undergoing the Convergent procedure from the time of the intervention through 30-days post intervention. There were no deaths, cardiac perforations or atrio-esophageal fistulas reported in the trial. Dr. DeLurgio presented the MAE rate of 7.8 percent in treatment arm, which was lower than the protocol pre-specified performance goal of 12 percent. There were also no long-lasting safety events observed in the trial. More detail can be found here.
     
    The trial enrolled 153 patients at 27 locations (25 in the United States and 2 in the United Kingdom). Patients were randomized at a rate of 2:1 and received either the hybrid Convergent procedure or an endocardial catheter ablation alone. Dr. David DeLurgio, M.D., of Emory St. Joseph’s Hospital in Atlanta, was the trial’s national principal investigator.
     
    “This is one of the most highly anticipated trials in the Afib space in many years because of the potential to effectively treat patients who are difficult to treat. I’m very pleased about the results of the trial, which showed an 18 percent difference between the Convergent arm and the control arm in evaluable patients at 12 months,” said Dr. DeLurgio. “Additionally, the measure of Afib burden reduction of greater than 90 ercent was remarkable and much better than expected. The data presented showed a greater than 23 percent advantage for the Convergent arm over the control arm. Based on these findings, epicardial and endocardial ablation using the hybrid Convergent procedure could prove to be a preferred therapy for patients with advanced forms of Afib.”
     
    Afib affects over 33 million people worldwide and approximately 70 percent have persistent and longstanding persistent Afib.1 Afib increases the risk of stroke and is linked with increased risk of mortality.
     
    “Most importantly, in keeping with the AtriCure mission, we look forward to working interactively with the FDA towards the approval of the therapy, which will facilitate targeted training and a more informed physician-patient discussion,” said Mr. Carrel.

    The EPi-Sense device and hybrid procedure are investigational and not approved in the US for the treatment of Afib. The data analyses presented have not been reviewed by FDA.

    The CONVERGE IDE trial is a landmark prospective, superiority, randomized controlled pivotal trial to evaluate the overall success of the hybrid Convergent ablation to endocardial catheter ablation for patients with persistent or long-standing persistent Afib. The procedure combines a minimally invasive, closed chest epicardial ablation performed by a surgeon with endocardial catheter ablation performed by an electrophysiologist.

    Reference 
    1 Berisso et al. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014; 6: 213–220.
    Related Searches
    • Cardiovascular
    Related Knowledge Center
    • Cardiovascular
    Suggested For You
    Breakthrough Device Designation Granted for New Neuromodulation Platform Breakthrough Device Designation Granted for New Neuromodulation Platform
    Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech
    Improved Outcomes Proven With Insulet’s Omnipod 5 System Improved Outcomes Proven With Insulet’s Omnipod 5 System
    Masimo Launches Single-Patient-Use rainbow SuperSensor in Europe Masimo Launches Single-Patient-Use rainbow SuperSensor in Europe
    Vertigo Treatment Receives FDA Breakthrough Device Designation Vertigo Treatment Receives FDA Breakthrough Device Designation
    FDA Approves TransMedics FDA Approves TransMedics' OCS Heart System for Donor Hearts
    RonovoRx RonovoRx's RenovoCath Earns New FDA 510(k)
    Bright Future Ahead for Renal Denervation Bright Future Ahead for Renal Denervation
    Acutus Medical Receives FDA Clearance for AcQMap 8 Software Upgrades Acutus Medical Receives FDA Clearance for AcQMap 8 Software Upgrades
    FDA Approves ZOLL FDA Approves ZOLL's remedē for Central Sleep Apnea
    Early Catheter Ablation of VT Outperforms Conventional Medical Therapy Early Catheter Ablation of VT Outperforms Conventional Medical Therapy
    Study: Human Oversight ECG Monitors Outperform AI-Dependent Monitoring Study: Human Oversight ECG Monitors Outperform AI-Dependent Monitoring
    Abbott Fined $160M to Resolve Medicare Diabetes Lawsuit Abbott Fined $160M to Resolve Medicare Diabetes Lawsuit
    Non-Profit Group Launches Initiative to Diversify Medtech Workforce Non-Profit Group Launches Initiative to Diversify Medtech Workforce
    BioFourmis BioFourmis' Digital Heart Failure Therapeutic Earns Breakthrough Status

    Related Content

    • Breakthrough Device Designation Granted for New Neuromodulation Platform

      Breakthrough Device Designation Granted for New Neuromodulation Platform

      In a pilot study treating refractory epilepsy with Neuroelectrics’ Starstim platform, patients experienced a 44 percent median reduction in seizure frequency.
      Business Wire 09.22.21

    • Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech

      Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech

      Electroducer Sleeve based on a medical technique called Direct Wire Pacing, which was invented by the company’s founder.
      Electroducer 09.21.21

    • Improved Outcomes Proven With Insulet’s Omnipod 5 System

      Improved Outcomes Proven With Insulet’s Omnipod 5 System

      Studies show the automated insulin delivery system improved HbA1c nearly one percentage point in kids and 0.60 percent in adolescents and adults.
      Business Wire 09.16.21


    • Patient Monitoring
      Masimo Launches Single-Patient-Use rainbow SuperSensor in Europe

      Masimo Launches Single-Patient-Use rainbow SuperSensor in Europe

      Uses 12 LEDs to simultaneously offer 12 blood constituent parameters noninvasively and continuously.
      Business Wire 09.13.21

    • Vertigo Treatment Receives FDA Breakthrough Device Designation

      Vertigo Treatment Receives FDA Breakthrough Device Designation

      The device's developer—Otolith Labs—closes $3.3 million in seed financing.
      Business Wire 09.13.21


      Trending
      • 5 Ways Plastics Revolutionized The Healthcare Industry | Medical Product Outsourcing
      • Anumana's ECG Pulmonary Hypertension AI Algorithm Gains Breakthrough Status | Medical Product Outsourcing
      • FDA Clears Masimo's Neonatal RD SET Pulse Oximetry Sensors With Improved Accuracy Specifications | Medical Product Outsourcing
      • Medtronic, DaVita To Create New Kidney Care Firm | Medical Product Outsourcing
      • 7 Steps To Create Your Own Medical Device Marketing Plan | Medical Product Outsourcing
      Breaking News
      • New Breast Implant Surgery Guidelines to Enhance Patient Safety
      • Rhythm Management Group Debuts RhythmSynergy Tech Platform
      • FDA Approves Trial Completion for Virtual Incision's MIRA Platform
      • Thermo Fisher Scientific, Matrix Clinical Trials Enhance Research Solutions
      • Medtronic, DaVita to Create New Kidney Care Firm
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Cybersecurity Challenges Leave Medical Device Makers Insecure
      • Contract Design for Medtech
      • Diabetes Medical Device Technology Update
      • Medtech Full-Service Outsourcing Q&A 2022

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports
      GC Rieber Foundations Expand Philanthropic Efforts
      Coatings World

      Latest Breaking News From Coatings World

      ICP Receives ASC Innovation Award for Spray Foam That Meets Changing Environmental Regulations
      Pylon Coatings Uses Polygiene Biomaster & Verimaster for Antimicrobial Surface Protection
      Sto Corp. Recognized with Multiple Honors at the EIFS Hero Awards
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      New Breast Implant Surgery Guidelines to Enhance Patient Safety
      Rhythm Management Group Debuts RhythmSynergy Tech Platform
      FDA Approves Trial Completion for Virtual Incision's MIRA Platform
      Contract Pharma

      Latest Breaking News From Contract Pharma

      DFE Pharma Opens India CoE for Fast-Track Formulation Services
      Helsinn Establishes New R&D Hub in the U.S.
      CureVac, myNEO Partner on Antigen Targets for mRNA-Cancer Vax Development
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Shellworks Raises $6.2 Million in Seed Funding
      Ulta Beauty Reports Record First Quarter 2022 Results
      Carlyle To Acquire HCP Packaging
      Happi

      Latest Breaking News From Happi

      Honeywell Addresses Critical Issues Such as Sustainability, Workforce Training and Digitalization
      Monat Global Wins Four Stevie Awards in the 20th Annual American Business Awards
      Coty Expands Vegan Beauty Portfolio With New Rimmel Mascara
      Ink World

      Latest Breaking News From Ink World

      UK-Based Caps Cases Installs World’s First EFI Nozomi 14000 LED Digital Corrugated Press
      Sonoco Announces Transition of Chief Financial Officer
      Azelis Expands Presence in India
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Labelexpo Asia 2022 postponed
      Teklynx software helps Top Clean Injection validate labels
      Zeller+Gmelin named Berry Global’s 2021 Ink Supplier of the Year
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Rael Raises $35M in Series B Funding
      Schobertechnologies Offers Rotary Web-fed Converting Solutions
      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Toetal Solutions Raises $1.02 Million in New Financing
      ManaMed's ManaSport Wearable Ultrasound Earns FDA Nod
      Ekso Bionics Names Jerome Wong as Interim CFO
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      onsemi Recognized by Fortune 500 for Its Transformation Journey
      LG Display Presents AI-Driven NFT Artwork on Transparent OLED
      Joe Stockunas Joins SEMI as Americas President

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login